Clicky

TransCode Therapeutics, Inc.(RNAZ)

Description: TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts


Keywords: Cancer Biopharmaceutical Metastatic Cancer Preclinical Stage Product Treatment Of Metastatic Cancer

Home Page: www.transcodetherapeutics.com

RNAZ Technical Analysis

6 Liberty Square
Boston, MA 02109
United States
Phone: 857-837-3099


Officers

Name Title
Mr. Robert Michael Dudley Co-Founder, CEO, Pres & Director
Mr. Thomas A. Fitzgerald M.B.A. CFO, VP of Admin. & Director
Dr. Zdravka Medarova Ph.D. Co-Founder & CTO
Dr. Anna Moore Ph.D. Co-Founder, Scientific Advisor & Member of Scientific Advisory Board
Dr. Qiyong Peter Liu Ph.D. VP of R&D and Chief Scientist
Mr. Alan Freidman VP of Investor Relations

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.7189
Price-to-Sales TTM: 0
IPO Date: 2021-07-08
Fiscal Year End: December
Full Time Employees: 8
Back to stocks